×
×
×
×
×

Tell us once and we'll remember.

I'm an...

Don't worry, you can always change this selection using the icons at the top left of the site.
Marshall Gordon

Marshall Gordon

Director, Senior Research Analyst for Health Care
25 Years experience
17 Years at firm

Marshall is a Senior Research Analyst for Health Care at ClearBridge Investments. He joined ClearBridge in 2008 and has 25 years of investment industry experience.

Prior to joining ClearBridge, Marshall was a Health Care Analyst on the Large Cap Growth Team at Bear Stearns Asset Management. He was previously a Senior Analyst covering medical supplies & devices and an Associate Analyst covering U.S. major pharmaceuticals at Credit Suisse; an Associate Analyst covering global biotechnology at Sanford C. Bernstein; and an Associate in the Life Sciences Group at Lazard Freres.

Marshall received an M.B.A. from The University of Chicago and a B.S. in finance from The Wharton School of the University of Pennsylvania.

Marshall’s key ESG considerations for the health care sector include access to medicines; addressing unmet medical needs; governance (especially capital allocation and executive compensation); drug safety and efficacy; ethical sales and marketing practices.

Experience

  • 25 years of investment industry experience
  • Joined ClearBridge Investments in 2008
  • Bear Stearns Asset Management - Health Care Analyst, Large Cap Growth Team
  • Credit Suisse – Senior Analyst, Medical Supplies & Devices
  • Credit Suisse – Associate Analyst, U.S. Major Pharmaceuticals
  • Sanford C. Bernstein – Associate Analyst, Global Biotechnology
  • Lazard Freres – Associate, Life Sciences Group
  • M.B.A. from The University of Chicago
  • B.S. in finance from The Wharton School of the University of Pennsylvania

Perspectives

  • Health Care Innovation Under Trump 2.0
    Health care analysts assess the prospects for clinical breakthroughs in biopharmaceuticals and medical devices under a new administration.
  • AI Sustainability Opportunities and Risks
    ESG Investment 1Q24: As AI develops and hits multiple inflexion points over the next few years, companies across ClearBridge portfolios will need to negotiate a variety of sustainability-related AI opportunities and risks.
  • The Diabetes and Obesity Market Opportunity
    Analysts Marshall Gordon and Brittany Henderson discuss the leading pharmaceuticals and medical devices available for addressing these chronic conditions.
MORE